Evonik expands production capacity for DL- methionine in Singapore

* An additional 40,000 metric tons of MetAMINO® per year from Singapore
* Consistent implementation of methionine asset strategy, safeguarding long-term global supply security
* Reducing carbon footprint from Evonik’s DL-methionine production in Singapore

**Essen, Germany.** Evonik is expanding its capacity to produce MetAMINO® (DL-methionine) on Jurong Island, Singapore, by 40,000 metric tons to around 340,000 metric tons per year. The high double-digit million euro investment in this further technological development is to reach target capacity by the third quarter of 2024. The planned process optimization measures will improve the carbon footprint of MetAMINO® produced in Singapore by six percent.

"Increasing capacity for MetAMINO® production in Singapore is another important step in the consistent implementation of our global methionine asset strategy, further improving supply security for our customers in Asia," says Dr. Gaetano Blanda, head of Animal Nutrition business line. "In the face of fragile supply chains, our strategy of producing MetAMINO® in three different regions of the world has proven its value to our customers."

At the core of the methionine strategy are the three production hubs in Singapore, Mobile (Alabama, USA) and Antwerp (Belgium). All three of Evonik's world-scale plants are based on best-in-class technologies and are designed to grow with the expanding global market through modular expansions.

Evonik's methionine plants in Singapore, which came on stream in 2014 and 2019, were already the largest production complex for DL-methionine in the world, with an annual capacity of around 300,000 metric tons of MetAMINO®. "The additional capacity of 40,000 metric tons is primarily intended to accompany the growth of our customers in Asia and continue to offer the highest product

9 March 2023

**Main press contact Yama Olumi**

Head of Market Communications Animal Nutrition

Phone + 49 6181 59-12437

yama.olumi@evonik.com

**Alternative press contact Dr. Jürgen Krauter**

Head of Market Communications Evonik

Phone +49 6181 59-6847

juergen.krauter@evonik.com

**Evonik Industries AG** Rellinghauser Straße 1-11

45128 Essen Germany

Phone +49 201 177-01

[www.evonik.com](http://www.evonik.com/)

Supervisory BoardBernd Tönjes, ChairmanExecutive BoardChristian

Kullmann, ChairmanDr. Harald Schwager, Deputy ChairmanThomas Wessel, Ute Wolf

Registered Office is Essen Register Court Essen Local Court

quality and security of supply – now even more sustainably," says Noel Kim, head of Region Asia for Evonik Animal Nutrition.

The company has succeeded in maintaining its technology and cost leadership in DL-methionine for decades by continuously optimizing its processes and equipment: "We are particularly proud of the highly innovative new processes that are now being implemented in Singapore", says Dr. Jan-Olaf Barth, head of Evonik's Essential Nutrition product line. "For example, we are taking another major step toward process efficiency and reducing our carbon footprint by implementing an electrolysis unit for green hydrogen supply and various energy integration measures."

These technological adjustments are an important building block in the sustainability strategy of the Nutrition & Care division. The carbon footprint of the additional volume will be reduced by 50 percent thanks to process improvement measures. This reduces the carbon footprint of the entire MetAMINO® production in Singapore by six percent.

In the United States, a new plant for methyl mercaptan production is currently being built at the methionine hub in Mobile, further

strengthening Evonik’s ability to offer reliable and cost-optimized supply and reducing the carbon footprint of DL-methionine from this site by about seven percent. Having a fully integrated ‘Verbund’ means Evonik will be able to produce all the necessary precursors for DL-methionine on site in 2024, as it already does at its other hubs. Additionally, in 2022, Evonik further developed and expanded the production facility for MMP (methylmercapto- propionaldehyde) in Wesseling (Germany), reinforcing the European methionine hub in Antwerp (Belgium).

Methionine is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein. Animal Nutrition is part of Evonik's Nutrition & Care Division and makes a major contribution to the profitable growth of Nutrition & Care through its self-financing power.

**Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

**About Nutrition & Care**

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment.

Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.